The phenomena of signal transduction is central to a myriad of critical functions in the molecular and cellular biology of almost all cells and organisms. Nowhere is this more evident than in the area of growth regulation. Increasing evidence has placed changes in and/or alterations of functions of important growth regulatory signaling pathways at the center of the pathogenesis of a number of human cancers. This program project will be a coordinated research effort directed at a number of candidate changes which are believed to play a role in some malignancies. The expertise and experience brought to bear in this research will cover a number of the important areas of signaling in oncogenesis including signaling through and blockade of type I receptor tyrosine kinases, alterations in the regulation of critical components of the PI3 kinase pathway, changes in the intracellular signaling through ras/mek/erk pathway, modulation of signals in the androgen response pathway and signaling with results in changes in important structural proteins involved in the transition from normal to malignant cells. This research is not designed to cover all areas of signal transduction and oncogenesis, but rather will capitalize on the expertise of project leaders and laboratories involved in the above mentioned areas to synergize overlapping research efforts in this important area of cancer biology. We feel the likelihood of important findings in both basic and translational research results from these efforts is high.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA032737-19
Application #
6657459
Study Section
Special Emphasis Panel (ZCA1-GRB-W (J1))
Program Officer
Spalholz, Barbara A
Project Start
1982-04-01
Project End
2007-06-30
Budget Start
2003-09-26
Budget End
2004-06-30
Support Year
19
Fiscal Year
2003
Total Cost
$1,661,328
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
O'Brien, Neil A; McDonald, Karen; Tong, Luo et al. (2014) Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res 20:3507-20
Short, John D; Dere, Ruhee; Houston, Kevin D et al. (2010) AMPK-mediated phosphorylation of murine p27 at T197 promotes binding of 14-3-3 proteins and increases p27 stability. Mol Carcinog 49:429-39
Klichko, Yaroslav; Liong, Monty; Choi, Eunshil et al. (2009) Mesostructured Silica for Optical Functionality, Nanomachines, and Drug Delivery. J Am Ceram Soc 92:s2-s10
Lu, Jie; Chan, Lai; Fiji, Hannah D G et al. (2009) In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Mol Cancer Ther 8:1218-26
Short, John D; Houston, Kevin D; Dere, Ruhee et al. (2008) AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. Cancer Res 68:6496-506
Lu, Jie; Choi, Eunshil; Tamanoi, Fuyuhiko et al. (2008) Light-activated nanoimpeller-controlled drug release in cancer cells. Small 4:421-6
Liong, Monty; Lu, Jie; Kovochich, Michael et al. (2008) Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2:889-96
Watanabe, Masaru; Fiji, Hannah D G; Guo, Lea et al. (2008) Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. J Biol Chem 283:9571-9
Lu, Jie; Liong, Monty; Sherman, Sean et al. (2007) Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells. Nanobiotechnology 3:89-95
Lu, Jie; Liong, Monty; Zink, Jeffrey I et al. (2007) Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 3:1341-6

Showing the most recent 10 out of 213 publications